GBI Research, Feb 2011, Pages: 195
. In addition, the report also includes insights into the antibacterialR&D pipeline.
Report is built using data and information sourced from proprietary databases, primary and secondary research and in-house
Global Markets Direct, Nov 2010, Pages: 67
classes in the Nippon Shinyaku Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows
GBI Research, Dec 2011, Pages: 86
in the market will not be corrected by new product launches of pipeline molecules. Pharmaceutical companies show less interest in antibacterialR&D due to low Return on Investment (RoI). The lifespan of antibacterials is frequently
Global Markets Direct, Nov 2011, Pages: 57
new drug targets and therapeutic classes in the Biota Holdings Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities
Global Industry Analysts, Inc., Feb 2010, Pages: 825
are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses
Datamonitor, April 2011, Pages: 40
Antibacterial therapy plays a vital role in sepsis treatment, although this does not directly translate into a high level of R&D interest
Despite the disappointing performance of Xigris, the sepsis
Global Markets Direct, Nov 2011, Pages: 100
potential of Intercell AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Intercell AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline
Global Industry Analysts, Inc., July 2009, Pages: 1810
Med Team Up for Antibody Therapeutics for Cancer
Stem Cell Research II-101
GSK Allies with Galapagos for Antiviral and Antibacterial
Development II-101
Eisai and BioArctic Ink Licensing Deal for BAN2401 II
Global Markets Direct, March 2011, Pages: 65
classes in the Nippon Shinyaku Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows
Global Markets Direct, Dec 2010, Pages: 78
potential of Intercell AG in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Intercell AG’s R&D portfolio and develop key strategic initiatives to reinforce pipeline
GlobalData, Nov 2010, Pages: 47
drug targets and therapeutic classes in the Anacor Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities
Global Markets Direct, Nov 2010, Pages: 47
drug targets and therapeutic classes in the Anacor Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities
Global Markets Direct, Dec 2010, Pages: 72
and therapeutic classes in the Bausch & Lomb Incorporated’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows
Datamonitor, May 2009, Pages: 79
, despite the costs and risks involved in drug development, the pharma industry is finding new ways to streamline the R&D process in an effort to increase efficiency and output.
- Overview of ongoing trends
Global Markets Direct, Dec 2010, Pages: 64
.
- Assess the growth potential of Wockhardt Limited in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Wockhardt Limited’s R&D portfolio and develop key strategic
GlobalData, Nov 2010, Pages: 28
Technology Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Global Markets Direct, Nov 2010, Pages: 28
Technology Ltd’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Global Industry Analysts, Inc., Oct 2010, Pages: 565
profiles are mostly extracted from URL research and reported select online sources.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3
Espicom Business Intelligence Ltd, April 2006, Pages: 1026
, with the establishment of new clinical R&D laboratories in China and Thailand, and new drugs launches in South Korea and Vietnam.
Key Partnering Alliances
Sosei: On 22nd February 2005, Sosei announced it had licensed
